Fair Value Calculator Fair Value Calculator
EN DE

CRESSAN (CRESSAN) Fair Value & Analysis

IN · Market cap ₹2.2B

C CRESSAN CRESSAN · BSE
Price₹2.41
Fair Value₹0.7300
Upside-69.7%
Quality33/100
Watch CRESSAN for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range ₹0.5100 – ₹0.9500

Fair value as of: Jul 5, 2026

From 9 valuation models · updated today

Share price −7.7% over the past month.

Price vs Fair Value (12 months)

₹5.12 ₹1.80 Fair Value ₹0.7300 Jun 2025 Jul 2026

12‑month range ₹1.80 – ₹5.12 · fair‑value band ₹0.5100 – ₹0.9500 · the ₹2.41 price screens above the ₹0.7300 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

CRESSAN (CRESSAN) currently trades at ₹2.41, while our model-based Fair Value estimate is ₹0.7300 — implying the stock looks roughly 69.7% overvalued today. We read business quality at 33/100 (below-average quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Trailing-twelve-month revenue stands at ₹868M. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹0.5100 (bear case) to ₹0.9500 (bull case); at ₹2.41, the current price sits above that range. The share trades about 55% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Revenue (TTM) ₹868M
Revenue growth (YoY) +599%
Net margin 0.0%
Return on equity 847%
Free cash flow −₹499M FY2023
Operating margin -86.6%
More key figures
EPS (TTM) ₹-0.0100

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

CRESSAN reported revenue of ₹325M in FY2024 versus ₹933K in FY2020, a compound +331.9%/yr. Reported net income was ₹6.8M in FY2024, compounding +250.7%/yr from FY2020.

Revenue +331.9%/yr
FY20 ₹933K
FY21 ₹1.8M
FY22 ₹868M
FY23 ₹2.0B
FY24 ₹325M
Net income +250.7%/yr
FY20 ₹45.2K
FY21 ₹2.7M
FY22 ₹60.8M
FY23 ₹137M
FY24 ₹6.8M

Is CRESSAN fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "CRESSAN Fair Value". https://www.fairvalue-calculator.com/stock/CRESSAN

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is CRESSAN (CRESSAN) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹0.7300 versus a price of ₹2.41 — about −70% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CRESSAN?
Our model-based fair value for CRESSAN is ₹0.7300 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹2.41.
What is the quality score of CRESSAN?
CRESSAN has a Quality Score of 33/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of CRESSAN (CRESSAN)?
CRESSAN reported trailing-twelve-month revenue of about ₹868M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of CRESSAN?
The net profit margin of CRESSAN is about 0.0%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.